SCHEMBL24100557

SCHEMBL24100557

BC(B)(Cl)CN(CCCl)c1ccc(CC(N)C(=O)NC(Cc2ccc(F)cc2)C(=O)OCC)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.44
▸ CYP3A4 P08684 3/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ ALOX15 P16050 2/20 0.43
▸ HIF1A Q16665 2/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ ABCB11 O95342 1/20 0.43
▸ CHRM2 P08172 1/20 0.43
▸ ADRA2A P08913 1/20 0.43
▸ CHRM1 P11229 1/20 0.43
▸ ACHE P22303 1/20 0.43
▸ PTGS1 P23219 1/20 0.43
▸ OPRM1 P35372 1/20 0.43
▸ DRD3 P35462 1/20 0.43
▸ SLC6A3 Q01959 1/20 0.43
▸ KCNH2 Q12809 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ CYP1A2 P05177 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25021304 0.94 NOS2 (0.37) LMNACYP3A4SMN1; SMN2KMT2AALDH1A1
Melphalan Flufenamide SCHEMBL24101233 0.91 LMNA (0.53) LMNACYP3A4SMN1; SMN2KMT2AALDH1A1
Melphalan Flufenamide SCHEMBL20208719 0.91 LMNA (0.53) LMNACYP3A4SMN1; SMN2KMT2AALDH1A1
Melphalan Flufenamide SCHEMBL18239898 0.91 LMNA (0.53) LMNACYP3A4SMN1; SMN2KMT2AALDH1A1
Melphalan Flufenamide SCHEMBL29375249 0.90 LMNA (0.52) LMNACYP3A4SMN1; SMN2KMT2AALDH1A1
SCHEMBL25021945 0.86 NOS2 (0.35) LMNAKDM4ENOS2NOS3NOS1
SCHEMBL24100754 0.86 LMNA (0.38) LMNACYP3A4SMN1; SMN2KMT2AALDH1A1
SCHEMBL25022672 0.85 NOS2 (0.36) LMNANOS2NOS3NOS1OPRK1
SCHEMBL25021253 0.85 LMNA (0.38) LMNACYP3A4SMN1; SMN2KMT2AALDH1A1
SCHEMBL24100695 0.85 CYP3A4 (0.49) LMNACYP3A4SMN1; SMN2KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210388024-A1 COMPOUNDS CONTAINING DEUTERIUM ONCOPEPTIDES AB (SE) 2021-12-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210388024-A1 COMPOUNDS CONTAINING DEUTERIUM DHX30, H1-10, REN LMNA 3001/4885CYP3A4 923/4885SMN1; SMN2 1801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback